Assessment of Risk in Thoracic Aortopathy Using 18F-Sodium Fluoride (AoRTAS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04083118 |
Recruitment Status :
Recruiting
First Posted : September 10, 2019
Last Update Posted : September 10, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Bicuspid Aortic Valve Thoracic Aortic Aneurysm Aortic Dissection | Diagnostic Test: clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI Diagnostic Test: Repeat 18F sodium fluoride PET/MRI |

Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Non-invasive Detection of Bicuspid Aortic Valve-Related Thoracic Aortopathy |
Actual Study Start Date : | April 1, 2019 |
Estimated Primary Completion Date : | August 3, 2021 |
Estimated Study Completion Date : | August 3, 2021 |

Group/Cohort | Intervention/treatment |
---|---|
Bicuspid aortic valve
80 patients with bicuspid aortic valve with or without an aortic aneurysm
|
Diagnostic Test: clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI
Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta Diagnostic Test: Repeat 18F sodium fluoride PET/MRI as per first study visit but without the PET/CT |
controls
20 healthy volunteer controls age and sex matched to 20 of the bicuspid aortic valve patients
|
Diagnostic Test: clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI
Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta |
- Aortic growth rate [ Time Frame: At 1-2 years after baseline visit ]Correlate baseline 18F sodium fluoride PET uptake with aortic growth rate, a marker of aortic wall remodelling, over 1-2 years
- Aortic stiffness [ Time Frame: 1-2 years (at second study visit) ]Aortic stiffness, which is a biomechanical marker of how elastic the aortic wall is, has been associated with increased aortic event rates in patients with connective tissue disorders. We will measure aortic stiffness using a variety of metrics including distensibility, elastic modulus, stiffness index (all MRI derived) and pulse wave velocity (deprived using application tomography). The change in aortic stiffness and baseline aortic stiffness will be correlated with baseline PET
- Wall shear stress [ Time Frame: 1 year (at baseline visit) ]Wall shear stress is extrapolated from 4D MRI and is proposed to be linked with histological changes in the aortic wall as well as increased dilatation. We will compare areas of high wall shear stress to those of high PET uptake.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Bicuspid aortic Valve or Age-sex matched healthy volunteer
Exclusion Criteria:
- Pregnancy
- eGFR < 30
- previous aortic replacement surgery
- previous aortic valve surgery
- contrast allergy
- other reason unable to undergo MRI

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04083118
Contact: Chris Coner | 0131 242 3326 ext 23326 | Chris.Coner@ed.ac.uk | |
Contact: David E Newby, MD, PhD, DSc | 0131 242 6515 ext 26515 | D.E.Newby@ed.ac.uk |
United Kingdom | |
University of Edinburgh | Recruiting |
Edinburgh, United Kingdom, EH16 4SB | |
Contact: Lynn Mckinlay 0131 242 6515 ext 26515 lynn.mckinlay@ed.ac.uk | |
Principal Investigator: Alexander J Fletcher, MD |
Principal Investigator: | Alexander J Fletcher, MD | University of Edinburgh |
Responsible Party: | University of Edinburgh |
ClinicalTrials.gov Identifier: | NCT04083118 |
Other Study ID Numbers: |
2018/0261 FS/19/15/34155 ( Other Grant/Funding Number: British Heart Foundation ) |
First Posted: | September 10, 2019 Key Record Dates |
Last Update Posted: | September 10, 2019 |
Last Verified: | September 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
positron emission tomography sodium fluoride bicuspid aortic valve thoracic aortic aneurysm aortopathy |
Aneurysm, Dissecting Aneurysm Aortic Aneurysm Aortic Aneurysm, Thoracic Heart Valve Diseases Vascular Diseases Cardiovascular Diseases Aortic Diseases Heart Diseases |
Listerine Fluorides Sodium Fluoride Cariostatic Agents Protective Agents Physiological Effects of Drugs Anti-Infective Agents, Local Anti-Infective Agents |